Waystar shares slip in Nasdaq debut after digital health company priced IPO in middle of range

Waystar shares slip in Nasdaq debut after digital health company priced IPO in middle of range


Waystar CEO: We're building a visible, recurring revenue business driving profitable growth

Waystar shares slid about 3% in their Nasdaq debut on Friday, after the health-care payment software vendor priced its IPO in the middle of the expected range.

The stock opened at $21 per share, below the IPO price of $21.50 late Thursday. Waystar said its expected price would be between $20 and $23 per share in May. Shares closed down more than 3% to $20.70 on Friday.

The IPO market has been largely dormant since late 2021 when the extended bull market turned and investors began to worry about a weakening economy. Few technology companies have been willing to try and go public since then, and no digital health companies had a public exit in 2023, according to a report from Rock Health.

But the broader venture-backed tech market may be beginning to thaw. Social media platform Reddit, data center connectivity chip vendor Astera Labs and data software management maker Rubrik have all gone public this year. Health tech company Tempus AI has also issued a preliminary prospectus this year.

Based on Waystar’s initial share price, the company’s market cap is about $3.5 billion. The stock is trading under the ticker symbol “WAY.”

Waystar offers health-care payment and revenue cycle management tools and facilitates more than 5 billion payment transactions annually, according to its prospectus. The company was formed in 2017 after the health-care payment companies Navicure and ZirMed merged.

“We’re excited about the opportunity to be a public company because we think it helps us with awareness, helps us with credibility, helps us improve our capital structure and allows for further investments in areas such as generative AI,” Waystar CEO Matt Hawkins told CNBC’s “The Exchange” Friday.

For the quarter ending March 31, Waystar generated revenue of $224.8 million, up 18% from $191.1 million in the same period last year. Waystar reported a net loss of $15.9 million for the quarter compared with $10.6 million a year ago.

The company said it plans to use the money from the offering to pay off existing debt. JPMorgan Chase, Goldman Sachs and Barclays are leading the offering.

WATCH: Tech IPOs face hurdle

Startup valuations' impact on IPOs



Source

Jim Cramer has faith in Danaher’s turnaround as life sciences comes back to life
Health

Jim Cramer has faith in Danaher’s turnaround as life sciences comes back to life

Life sciences stocks are seeing a resurgence — and that’s good news for Danaher . Connecting the dots to better times ahead for the struggling portfolio name, Jim Cramer thinks the industry turnaround is best illustrated by looking at Agilent Technologies ‘ recovery from a post-Covid rut. Shares are up around 50% from their April […]

Read More
‘Advice was so good,’ says CEO who used ChatGPT to pitch new ideas to AI versions of business icons
Health

‘Advice was so good,’ says CEO who used ChatGPT to pitch new ideas to AI versions of business icons

Joanna Stober, Midi Health CEO and co-founder, has never had an opportunity to run her business plans past legendary venture capital investor John Doerr, chairman at Kleiner Perkins. But that didn’t stop her from tapping Doerr, in an AI version, for advice on growing her startup, a virtual clinic offering midlife health care for women. […]

Read More
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
Health

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site

The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the […]

Read More